Breast Cancer Research and Treatment

, Volume 138, Issue 3, pp 931–939 | Cite as

Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer

  • Christopher R. FrieseEmail author
  • T. May Pini
  • Yun Li
  • Paul H. Abrahamse
  • John J. Graff
  • Ann S. Hamilton
  • Reshma Jagsi
  • Nancy K. Janz
  • Sarah T. Hawley
  • Steven J. Katz
  • Jennifer J. Griggs


Adjuvant endocrine therapy for breast cancer reduces recurrence and improves survival rates. Many patients never start treatment or discontinue prematurely. A better understanding of factors associated with endocrine therapy initiation and persistence could inform practitioners how to support patients. We analyzed data from a longitudinal study of 2,268 women diagnosed with breast cancer and reported to the Metropolitan Detroit and Los Angeles SEER cancer registries in 2005–2007. Patients were surveyed approximately both 9 months and 4 years after diagnosis. At the 4-year mark, patients were asked if they had initiated endocrine therapy, terminated therapy, or were currently taking therapy (defined as persistence). Multivariable logistic regression models examined factors associated with initiation and persistence. Of the 743 patients eligible for endocrine therapy, 80 (10.8 %) never initiated therapy, 112 (15.1 %) started therapy but discontinued prematurely, and 551 (74.2 %) continued use at the second time point. Compared with whites, Latinas (OR 2.80, 95 % CI 1.08–7.23) and black women (OR 3.63, 95 % CI 1.22–10.78) were more likely to initiate therapy. Other factors associated with initiation included worry about recurrence (OR 3.54, 95 % CI 1.31–9.56) and inadequate information about side effects (OR 0.24, 95 % CI 0.10–0.55). Factors associated with persistence included two or more medications taken weekly (OR 4.19, 95 % CI 2.28–7.68) and increased age (OR 0.98, 95 % CI 0.95–0.99). Enhanced patient education about potential side effects and the effectiveness of adjuvant endocrine therapy in improving outcomes may improve initiation and persistence rates and optimize breast cancer survival.


Breast neoplasms Aromatase inhibitors Selective estrogen receptor modulators Medication taking Health services research 



This work was funded by Grants R01 CA109696 and R01 CA088370 from the National Cancer Institute to the University of Michigan. Dr. Friese was supported by a Pathway to Independence Award from the National Institute for Nursing Research (R00NR01570). Dr. Katz was supported by an Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Sciences Research from the National Cancer Institute (K05CA111340). Dr. Jagsi was supported by a Mentored Research Scholar Grant from the American Cancer Society (MRSG-09-145-01). The collection of Los Angeles County cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code §103885. The National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract N01-PC-35139 was awarded to the University of Southern California. Contract N01-PC-54404 and agreement 1U58DP00807-01 were awarded to the Public Health Institute. The collection of metropolitan Detroit cancer incidence data was supported by the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract N01-PC-35145.

Conflict of interest

The authors declare they have no conflict of interest.

Ethical standards

Institutional Review Boards of the University of Michigan, the University of Southern California, and Wayne State University approved the study described in this work.


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  2. 2.
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53PubMedCrossRefGoogle Scholar
  3. 3.
    Yood MU, Owusu C, Buist DS et al (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206:66–75PubMedCrossRefGoogle Scholar
  4. 4.
    Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus 5 years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543–1549CrossRefGoogle Scholar
  5. 5.
    Sacco M, Valentini M, Belfiglio M et al (2003) Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol 21:2276–2281PubMedCrossRefGoogle Scholar
  6. 6.
    Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol 2012. doi: 10.1097/COC.0b013e3182436ec1 Accessed 29 Sept 2012
  7. 7.
    Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529–537PubMedCrossRefGoogle Scholar
  8. 8.
    Partridge AH, Lafountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562PubMedCrossRefGoogle Scholar
  9. 9.
    Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606PubMedCrossRefGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2012. Accessed 1 Oct 2012
  11. 11.
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365PubMedCrossRefGoogle Scholar
  12. 12.
    Thuerlimann B (2001) International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast Cancer 8:294–297PubMedCrossRefGoogle Scholar
  13. 13.
    Davies C, Hongchao P, Godwin J, et al (2012) ATLAS. 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ disease: effects on outcome in the first and in the second decade after diagnosis. CTRC–AACR San Antonio Breast Cancer Symposium, San AntonioGoogle Scholar
  14. 14.
    Jin H, Tu D, Zhao N et al (2012) Longer-term outcomes of Letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 30(7):718–721PubMedCrossRefGoogle Scholar
  15. 15.
    Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643PubMedCrossRefGoogle Scholar
  16. 16.
    Henry NL, Giles JT, Ang D et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372PubMedCrossRefGoogle Scholar
  17. 17.
    Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J (2002) Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 94:1626–1634PubMedCrossRefGoogle Scholar
  18. 18.
    Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R (2006) Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987–2000. J Clin Oncol 24:872–877PubMedCrossRefGoogle Scholar
  19. 19.
    Hebert-Croteau N, Brisson J, Latreille J, Gariepy G, Blanchette C, Deschenes L (1999) Time trends in systemic adjuvant treatment for node-negative breast cancer. J Clin Oncol 17:1458–1464PubMedGoogle Scholar
  20. 20.
    Lash TL, Silliman RA, Guadagnoli E, Mor V (2000) The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer 89:1739–1747PubMedCrossRefGoogle Scholar
  21. 21.
    Atkins L, Fallowfield L (2006) Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271–2276PubMedCrossRefGoogle Scholar
  22. 22.
    Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328PubMedGoogle Scholar
  23. 23.
    Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315PubMedCrossRefGoogle Scholar
  24. 24.
    Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59:97–102PubMedCrossRefGoogle Scholar
  25. 25.
    Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45:431–439PubMedCrossRefGoogle Scholar
  26. 26.
    Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220PubMedCrossRefGoogle Scholar
  27. 27.
    Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology. 71:1–9PubMedGoogle Scholar
  28. 28.
    DiMatteo MR (2004) Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42:200–209PubMedCrossRefGoogle Scholar
  29. 29.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497PubMedCrossRefGoogle Scholar
  30. 30.
    Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor: positive breast cancer. J Clin Oncol 26:549–555PubMedCrossRefGoogle Scholar
  31. 31.
    Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG (2009) Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 119:390–397PubMedCrossRefGoogle Scholar
  32. 32.
    Piette JD, Heisler M (2004) Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care 10:861–868PubMedGoogle Scholar
  33. 33.
    Piette JD, Heisler M, Krein S, Kerr EA (2005) The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 165:1749–1755PubMedCrossRefGoogle Scholar
  34. 34.
    Griggs JJ, Hawley ST, Graff JJ et al (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30:3058–3064PubMedCrossRefGoogle Scholar
  35. 35.
    Dillman DA (2007) Mail and Internet Surveys: the tailored design method, 2nd edn. Wiley, New YorkGoogle Scholar
  36. 36.
    Hamilton AS, Hofer TP, Hawley ST et al (2009) Latinas and breast cancer outcomes: population-based sampling, ethnic identity, and acculturation assessment. Cancer Epidemiol Biomarkers Prev 18:2022–2029PubMedCrossRefGoogle Scholar
  37. 37.
    Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567PubMedCrossRefGoogle Scholar
  38. 38.
    Janz NK, Hawley ST, Mujahid MS et al (2011) Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer 117:1827–1836PubMedCrossRefGoogle Scholar
  39. 39.
    Danilak M, Chambers CR (2012) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract Aug 15 (epub ahead of print)Google Scholar
  40. 40.
    Yen TW, Czypinski LK, Sparapani RA et al (2011) Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer 117:398–405PubMedCrossRefGoogle Scholar
  41. 41.
    Yung RL, Hassett MJ, Chen K (2012) et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst 104:1102–1105PubMedCrossRefGoogle Scholar
  42. 42.
    Lipscomb J, Gillespie TW, Goodman M et al (2012) Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 133:285–296PubMedCrossRefGoogle Scholar
  43. 43.
    Kimmick GG, Anderson R, Camacho F et al (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445–3551PubMedCrossRefGoogle Scholar
  44. 44.
    Land SR, Cronin WM, Wickerham DL et al (2011) Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res 4:1393–1400CrossRefGoogle Scholar
  45. 45.
    Lin JH, Zhang SM, Manson JE (2011) Predicting adherence to tamoxifen and breast cancer adjuvant therapy and prevention. Cancer Prev Res. 4:1360–1365CrossRefGoogle Scholar
  46. 46.
    Friese CR (2012) Disparities in breast cancer care delivery: solving a complex puzzle. Breast Cancer Res Treat 133:297–299PubMedCrossRefGoogle Scholar
  47. 47.
    Janz NK, Becker MH (1984) The health belief model: a decade later. Health Educ Q 11:1–47PubMedCrossRefGoogle Scholar
  48. 48.
    Wu XC, Lund MJ, Kimmick GG et al (2011) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for loco regional breast cancers. J Clin Oncol 30(2):142–150PubMedCrossRefGoogle Scholar
  49. 49.
    Oberguggenberger A, Sztankay M, Beer B, et al (2012) Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer 12:474. Accessed on 22 Oct 2012Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Christopher R. Friese
    • 1
    Email author
  • T. May Pini
    • 2
  • Yun Li
    • 1
  • Paul H. Abrahamse
    • 1
  • John J. Graff
    • 3
  • Ann S. Hamilton
    • 4
  • Reshma Jagsi
    • 1
  • Nancy K. Janz
    • 1
  • Sarah T. Hawley
    • 1
  • Steven J. Katz
    • 1
  • Jennifer J. Griggs
    • 1
  1. 1.University of MichiganAnn ArborUSA
  2. 2.M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Cancer Institute of New Jersey, Robert Wood Johnson Medical SchoolNew BrunswickUSA
  4. 4.Keck School of Medicine, University of Southern CaliforniaLos AngelesUSA

Personalised recommendations